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Abstract
Background: Lyme disease, the most common vector-borne infection in North America, is
increasingly reported. When the characteristic rash, erythema migrans, is not recognized and
treated, delayed manifestations of disseminated infection may occur. The accuracy of diagnosis and
treatment of early Lyme disease in the community is unknown.
Methods: A retrospective, consecutive case series of 165 patients presenting for possible early
Lyme disease between August 1, 2002 and August 1, 2007 to a community-based Lyme referral
practice in Maryland. All patients had acute symptoms of less than or equal to 12 weeks duration.
Patients were categorized according to the Centers for Disease Control and Prevention criteria
and data were collected on presenting history, physical findings, laboratory serology, prior
diagnoses and prior treatments.
Results: The majority (61%) of patients in this case series were diagnosed with early Lyme disease.
Of those diagnosed with early Lyme disease, 13% did not present with erythema migrans; of those
not presenting with a rash, 54% had been previously misdiagnosed. Among those with a rash, the
diagnosis of erythema migrans was initially missed in 23% of patients whose rash was subsequently
confirmed. Of all patients previously misdiagnosed, 41% had received initial antibiotics likely to be
ineffective against Lyme disease.
Conclusion: For community physicians practicing in high-risk geographic areas, the diagnosis of
Lyme disease remains a challenge. Failure to recognize erythema migrans or alternatively, viral-like
presentations without a rash, can lead to missed or delayed diagnosis of Lyme disease, ineffective
antibiotic treatment, and the potential for late manifestations.
Background
Lyme disease is a multisystem infection caused by the spi-
rochete Borrelia burgdorferi sensu stricto in North America.
With over 27,000 new cases reported yearly, Lyme disease
is the most commonly reported vector-borne disease in
the United States, with the number of reported cases more
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than doubling between 1992 and 2006 [1]. Additional
studies have shown that actual cases of Lyme disease may
exceed reported cases by a factor of 6 to 12 in endemic
areas [2,3]. The hallmark of early disease is a localized
skin infection, erythema migrans (EM), which occurs at
the site of the bite of an infected tick. Accurate identifica-
tion of this rash is essential to a correct diagnosis, as serol-
ogy is negative in 60% of patients early in infection when
initial evaluation is likely to occur [4]. The ability of clini-
cians to accurately diagnose EM is unclear, but both over
and under diagnosis have been reported [5,6]. Addition-
ally, some reports suggest that up to 10% of patients with
acute Lyme disease do not have a rash [7]. When
untreated, the initial localized cutaneous infection may
then spread hematogenously to other areas of the skin,
nervous system, heart and joints.
The Centers for Disease Control and Prevention (CDC)
establishes clinical and serologic criteria to standardize
surveillance for Lyme disease [8]; these were recently
updated in 2008 (Table 1) [9]. These criteria rely heavily
on accurately identifying objective findings, especially
EM, which has been shown to contribute to 70% of all
diagnoses [10]. However, if the EM rash is initially missed,
misdiagnosed or inadequately treated, the diagnosis of
Lyme disease may be significantly delayed or missed alto-
gether [6,11]. In addition, while CDC serologic criteria
were originally designed for surveillance purposes, labora-
tory confirmation based on these criteria has been rou-
tinely recommended for use in individual, clinical
diagnosis by such authorities as the CDC and the Infec-
tious Disease Society of America (IDSA) [12,13]. Misinter-
pretation of such guidelines and the potential for clinician
over-reliance on serologic confirmation for diagnosis
could lead to under-diagnosis in patients with a clinically
significant EM rash and false negative serology [14]. More-
over, outside of research settings there is no clinically rec-
ommended test (such as PCR or B. burgdorferi culture) to
confirm the diagnosis of early Lyme disease if EM is not
present.
The recently revised CDC case definition of Lyme disease
now includes "probable" and "suspected" case classifica-
tions (Table 1). Viral-like presentations without a rash, in
conjunction with positive serology, can now be consid-
ered part of the clinical spectrum of B. burgdorferi infection
[15]. Such presentations did not meet prior CDC case def-
initions and only recently can be considered "probable
Lyme disease" [8,9]. It is unknown whether this presenta-
tion is widely recognized by the general medical commu-
nity [12].
Accurate diagnosis of early Lyme disease is important, as
delayed diagnosis, missed diagnosis, or inadequate treat-
ment with non-recommended antibiotics may have seri-
ous sequelae. A previous treatment trial with
azithromycin, an antibiotic not currently recommended
as first-line therapy, showed a significantly higher rate of
post-treatment complications when compared with
amoxicillin, a currently recommended antibiotic [16].
Further, persistent symptoms after treatment of early
Lyme disease is well described and may be more common
in patients with delayed diagnosis [17-19]. Estimating the
incidence of post-treatment symptoms to be 5–15% and
the number of new reported and unreported cases of
Lyme disease to be between 160,000 and 320,000 cases a
year predicts as many as 8,100 to 48,600 new patients
with post treatment symptoms a year [18,20,21].
The objectives of this retrospective review are to character-
ize a group of community-based, ambulatory patients pre-
senting for evaluation of possible early Lyme disease, to
determine how many of these patients meet CDC criteria,
and to characterize patterns of care and treatment for
these patients. Few such reviews exist which address the
translation of Lyme disease guidelines and recommenda-
tions to the community practice of medicine [22].
Methods
Patients and Setting
This review included consecutive patients presenting
between August 1, 2002 and August 1, 2007 to a general
internist with infectious disease training (JA) for possible
early Lyme disease. Patients were either self or physician
referred for consultation. The practice is located in Balti-
Table 1: 2008 CDC Lyme Disease Surveillance Case Definition [9]
Confirmed a. a case of EM with a known exposure *
b. a case of EM with laboratory evidence of infection and without a known exposure
c. a case with at least one late manifestation that has laboratory evidence of infection
Probable Any other case of physician-diagnosed Lyme disease that has laboratory evidence of infection
Suspected a. a case of EM where there is no known exposure and no laboratory evidence of infection
b. a case with laboratory evidence of infection but no clinical information available (e.g. a laboratory report)
* exposure is defined as having been (less than or equal to 30 days before onset of EM) in wooded, brushy, or grassy areas (i.e. potential tick 
habitats) in a county in which Lyme disease is endemic (in which at least two confirmed cases have been acquired in the county or in which 
established populations of a known tick vector are infected with B. burgdoreri). A history of tick bite is not required.BMC Infectious Diseases 2009, 9:79 http://www.biomedcentral.com/1471-2334/9/79
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more County, Maryland, a region characterized as high
risk for Lyme disease.
Measurements
A complete history and physical exam, including a total-
body skin exam, were performed. If a skin rash meeting
CDC criteria for EM was not seen, ELISA and western blot
serologies for immunoglobulin M or immunoglobulin G
antibodies was obtained. Extensive evaluation for possi-
ble alternative diagnoses was initiated if the patient did
not have a diagnostic EM rash at the time of consultation,
or if the medical history, physical exam or laboratory find-
ings were suggestive. All subjective and objective signs and
symptoms were documented on a standardized form, and
any relevant medical records were reviewed. To assess
neurologic involvement, documentation of cerebrospinal
fluid analysis, central nervous system imaging, and nerve
conduction studies was also reviewed. Patients also self-
reported prior diagnoses, symptom explanations, and
antibiotic and glucocorticosteroid use prior to presenta-
tion. Antibiotics considered ineffective for treatment of
Lyme disease included 1st generation cephalosporins, qui-
nolones, and short-course macrolides such as 5-day azi-
thromycin "Z-packs" or 7–10 days of clarithromycin [12].
Definition of Cases
We included all patients referred with acute symptoms
less than or equal to 12 weeks of duration. Where sero-
logic confirmation was necessary, ELISA and Western
Blots were performed by a generally available commercial
lab and interpreted according to CDC criteria [23].
Confirmed early Lyme disease was defined by the CDC case
definition [1], including either a) an EM rash or b) posi-
tive serology in the presence of an objective finding of cra-
nial neuritis, meningitis, carditis or joint swelling. Clinical
diagnosis of EM was made by a consulting physician (JA)
with a high rate of specificity in EM diagnosis [24].
Probable early Lyme disease was defined by the recently
adopted CDC case definition [9] as presentation with an
acute illness, no physician-documented EM, and positive
serologic confirmation, including the presence of both a
positive ELISA and 2 or more bands on the IgM western
blot.
Alternative acute presentations which did not meet criteria
for early or probable early Lyme disease were further cate-
gorized into three groups.
a. Patients with specific, non-dermatologic diagnoses,
including infections other than Lyme disease
b. Patients with dermatologic diagnoses
c. Patients with non-specific, viral-like syndromes without
evidence of an alternative infectious process.
Case characteristics were analyzed using simple percent-
ages and Fisher's exact tests.
This study was approved by the Institutional Review
Board of the Johns Hopkins University School of Medi-
cine and written, signed consent was obtained for all fig-
ures containing patient photographs.
Results
Of the 165 patients evaluated during the study period,
101 were diagnosed with either confirmed or probable
early Lyme disease, and 64 were found to have an acute ill-
ness that either did not meet study criteria or met alterna-
tive diagnostic criteria (Figure 1). Of the 101 patients with
early Lyme, 88 had an EM rash as part of their acute ill-
ness, with multiple EM lesions occurring in 13% of these
patients. Of the remaining 13 seropositive patients not
presenting with a diagnostic EM, 6 presented with objec-
tive neurologic or cardiac manifestations, and 7 had a
viral-like illness. Thus, a total of thirteen (12.9%) of the
101 patients diagnosed with Lyme disease did not present
with an EM rash.
Among the 88 patients presenting with EM, 20 (23%) had
been previously misdiagnosed without the initiation of
Classification of 165 patients referred for possible acute  Lyme disease Figure 1
Classification of 165 patients referred for possible 
acute Lyme disease. * Presenting objective findings 
include: 2 patients with radiculopathy, 2 with VII nerve palsy, 
1 with carditis, 1 with arthritis. † Percentages in this row rep-
resent proportion of all referred acute patients. ‡ 2 patients 
were excluded from this analysis because no confirmatory 
serology was drawn after antibiotics were initiated.
                                 165
                             Acute ( 12 weeks) 
    64                  101 
(38.8%)                                                                       (61.2%) 
                         Other                                                                   Lyme Diagnosis 
      
25
(15.2%)
†
Viral-like 
illness 
17
(10.3%)
Viral-like 
illness 
with
alternative 
diagnosis
22
(13.3%)
Dermatologic
diagnosis
88
(53.3%)
EM (+) 
6
(3.6%)
EM (-) 
Sero (+), 
Objective 
findings*
7
(4.2%)
EM (-), 
Sero (+), 
Viral-like 
illness 
16
‡            0
    (69.6%)                            (0.0%) 
    Antibiotic exposure                         Antibiotic exposure   
    prior to confirmatory                       prior to confirmatory 
    serology                                        serologyBMC Infectious Diseases 2009, 9:79 http://www.biomedcentral.com/1471-2334/9/79
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appropriate antibiotic treatment (Table 2). In 13 (65%) of
these 20 patients, the rash had been observed but incor-
rectly identified or treated. Rashes were often misidenti-
fied by clinicians and patients as a spider bite, cellulitis, or
shingles (data not shown). For the remaining 7, the EM
was not discovered or was not present at the time of initial
misdiagnosis. Fourteen (70%) of those patients with EM
who were previously misdiagnosed with another illness
had positive serology for Lyme disease.
Of the 13 seropositive patients diagnosed with Lyme dis-
ease without an EM present, 7 (53.8%) had been previ-
ously misdiagnosed (Table 2). Misdiagnosis occurred
with greater frequency in patients with no EM and extra-
cutaneous, objective manifestations (83%) than in
patients with EM (23%: p = 0.004). Prior diagnoses given
to these misdiagnosed patients included diverticulitis,
acute coronary syndrome, sciatica, and lymphoma. Of all
misdiagnosed cases, 11 (41%) received an antibiotic not
recommended for treatment of Lyme disease and 8 (30%)
were exposed to steroids.
Sixty four patients with acute symptoms did not meet cri-
teria for confirmed or probable early Lyme disease (Figure
1). Twenty-five of these patients (39%) presented with
negative serology and an acute, viral-like illness without
objective findings. When prior antibiotic exposure was
assessed for these patients, 70% had received antibiotics
before diagnostic serology was obtained, compared with
none of the sero-positive patients presenting with similar
symptoms (p = 0.002). In 17 of these 64 patients (25%),
an alternative diagnosis was made, including parvovirus,
Ramsay Hunt syndrome or varicella zoster virus. A final
group of 22 patients (36%) had rashes failing criteria for
EM who received other dermatologic diagnoses, including
local hypersensitivity tick bite reactions, round lesions of
small size, or urticaria.
Discussion
In light of recently revised CDC guidelines, this review
highlights three major challenges continuing to face com-
munity practitioners: first, accurate diagnosis of EM, sec-
ond, the identification of viral-like illnesses without a rash
as possible Lyme disease, and third, appropriate antibiotic
selection in community settings where Lyme disease is
prevalent.
EM was the most common presentation of early Lyme dis-
ease in our series. However, prior misdiagnosis remained
common, confirming previous reports from other
endemic areas [6]. Patients and physicians often saw the
EM but were unaware of its significance, understandable
considering the substantial variation in its morphology
[5]. While 80% of EM in the United States are uniformly
red, only 19% have the stereotypical bull's eye appearance
[5]. While typically circular or oval, it can also be triangu-
lar, rectangular or distorted in other ways when occurring
in areas such as the neck [6]. Atypical features may include
erythema with central induration, urticarial like lesions,
confluent red-blue lesions mimicking ecchymosis, vesi-
cles mimicking shingles, and central necrosis mimicking
spider bites [6,25,26]. Examples of typical and atypical
lesions are shown in Figures 2, 3, 4, 5 and 6. In our series,
the most common misdiagnosis for EM was spider bite,
consistent with observations that spider bites may be
commonly over-diagnosed [27].
Even when a suspicious rash is found, there is no single,
independent element in the medical history or physical
exam highly sensitive for confirming the diagnosis of EM,
and the specificity of the finding is unclear [5]. No con-
firmatory tests (such as PCR or culture) are available to
community practitioners despite their potential utility in
early diagnosis, and serologies offer a 60% false negative
rate in the first weeks of infection [4,24,28]. Accurate diag-
nosis of EM requires an experienced clinical impression of
the rash's appearance [5]. EM may be missed if not specif-
ically sought on exam, as they are often asymptomatic,
unseen by the patient, and found in areas such as the back,
trunk and groin. In our series, several patients with an
eventual EM diagnosis either received an incomplete skin
exam or had a delayed EM appearance. Misidentification
of EM represents a serious problem in the community, as
opportunities for accurate diagnoses and appropriate
Table 2: Characteristics and presenting features of previously misdiagnosed patients (n = 27)
EM (+)
n = 88
EM (-),
Sero (+),
Objective findings
n = 6
EM (-),
Sero (+),
Viral-like illness
n = 7
Total
n = 101
Patients with prior misdiagnosis (% of all patients in category) 20 (22.7) 5 (83.3) 2 (28.6) 27 (26.7)
Sero (+) for early Lyme disease 14 5 2 21
Exposed to ineffective antibiotic prior to diagnosis 10 1 0 11
Exposed to steroids prior to diagnosis 6 2 0 8BMC Infectious Diseases 2009, 9:79 http://www.biomedcentral.com/1471-2334/9/79
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treatment wane after the rash disappears. Relying on
patient history or incomplete examination can thus leave
the physician without a hallmark of the disease.
The common misconception that a bull's eye EM is the
only diagnostic manifestation of Lyme disease continues
to mislead both patients and practitioners. The absence of
EM for 13% of our early Lyme cases highlights this dis-
crepancy, with the majority of these seropositive patients
(54%) developing only non-specific, viral-like illnesses
without objective manifestations. Little attention has
been afforded this presentation, despite the recognition
that it may account for up to 9–16% of all early cases
[15,29,30]. However, the IDSA guidelines for the manage-
ment of Lyme disease do not specifically address nor pro-
vide treatment options for this subset of patients [12] and
they are not included in treatment trials or long term out-
come studies [31,32]. Our data suggests that 7% (95% CI:
2%–12%) of all acute cases may present with a viral-like
illness and positive serology. Further, our identification of
a subset of seronegative patients presenting with similar,
non-specific viral-like illnesses of unknown etiology is
notable. It is unclear whether a proportion of these
patients represent probable cases who simply failed to
meet current serological criteria. Until more effective anti-
gen detection, PCR or culture become available, diagnosis
of non-specific, viral-like illnesses in Lyme endemic areas
will remain problematic. In high risk areas, clinicians
need to be aware of such presentations in order to mini-
mize misdiagnoses, missed treatment opportunities, and
the overall population burden of Lyme disease.
Atypical EM with previous misdiagnosis and treatment failure Figure 2
Atypical EM with previous misdiagnosis and treat-
ment failure. A 26 year old woman was diagnosed with a 
brown recluse spider bite and treated with oral cephalexin 
and prednisone for an erythematous lesion with a central 
eschar (panel A). Ten days later, she has persistent malaise 
and generalized aches and was seen by one of the authors 
(JA). She was found to have healing of the primary EM lesion 
with the appearance of new secondary lesions (panel B). 
Serology showed ELISA reactivity with positive confirmatory 
IgM and IgG western blots. Treatment with oral doxycycline 
resulted in a prompt response and resolution of the lesions 
and symptoms.
AB
Disseminated cutaneous EM lesions Figure 3
Disseminated cutaneous EM lesions. A 57 year old man 
was seen by his primary care physician for fever, fatigue, 
headache, and arthralgia and no specific diagnosis was made. 
He presented for re-evaluation to one of the authors (JA) 
four days later, after his wife noticed a rash. On examination, 
he had multiple target lesions. Serology showed ELISA reac-
tivity with positive confirmatory IgM and IgG western blots. 
Treatment with oral doxycycline resulted in a prompt 
response and resolution of the lesions and symptoms.
Typical disseminated EM lesions with VII nerve palsy Figure 4
Typical disseminated EM lesions with VII nerve palsy. 
An 18 year old man was seen for new VII nerve palsy. A com-
plete physical exam showed multiple lesions consistent with 
disseminated cutaneous Lyme disease. Serology for Lyme dis-
ease showed ELISA and IgM reactivity. Treatment with oral 
doxycycline resulted in a prompt resolution of the rash, with 
recovery of the VII nerve palsy over the next several weeks.BMC Infectious Diseases 2009, 9:79 http://www.biomedcentral.com/1471-2334/9/79
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Our patients with early Lyme disease defined by extracu-
tanous, objective neurologic or cardiac disease often had
systemic presentations with abdominal pain, chest symp-
toms or other atypical features. This misled clinicians to
treat incorrect etiologies, including diverticulitis, acute
coronary syndrome, sciatica, and lymphoma. Especially
confusing are systemic presentations with elevated AST
and ALT, previously reported in 37% of presenting
patients [33,34]. Chest or abdominal pain are uncommon
but elusive presentations of Lyme disease that may be due
to cardiac involvement or radiculopathy involving the
thoracic dermatomes [35-37].
Among previously misdiagnosed early Lyme patients,
41% received ineffective antibiotics which have been
associated with treatment failures and higher relapse rates
[11,12,38]. For misdiagnosed patients or those presenting
with a viral-like illness, administration of ineffective anti-
biotics may produce unintended consequences. In studies
showing suboptimal results with azithromycin, patients
were often seronegative after treatment [16], raising the
potential impact of sub-optimal therapy on seroconver-
sion and further complicating reliance on a serology-
based diagnosis [39]. In our series, seronegative patients
presenting with a viral-like illness were significantly more
likely to have been exposed to antibiotics prior to con-
firmatory serology than those who tested positive. The
impact of ineffective antibiotics on early Lyme disease
warrants further research.
The circumstances associated with steroid use in our series
were a presentation of VII nerve palsy (presumably
administered as treatment for idiopathic Bell's palsy) or a
diagnosis of spider bite. It is unclear what additional
impact the administration of steroids may have on the
natural history of Lyme disease in humans [40], however
steroid administration was shown to be required to
achieve high rates of central nervous system infection in
the Rhesus monkey model of neuroborreliosis [41].
This study has several limitations. Our inability to per-
form cultures or PCR on patient rashes left us without true
diagnostic confirmation of the presence or absence of EM,
particularly among those patients with atypical rashes.
The percentage of patients with misdiagnosed rashes that
showed serologic evidence of exposure to Borrelia burgdor-
feri (70%) is expected in the setting of early Lyme disease.
Despite the expected level of seroreactivity, we can not be
sure that the rashes we diagnosed were all due to Lyme
disease. However, physicians in community practice cur-
Misdiagnosis of flu-like illness with typical, non-bull's eye EM Figure 5
Misdiagnosis of flu-like illness with typical, non-bull's 
eye EM. A 45 year old man was seen for 'flu-like' symptoms 
and was diagnosed with a viral syndrome. Several days later 
he presented to one of the authors (JA) for re-evaluation of 
persistent symptoms. Complete physical exam showed a 
round, red, non-tender skin lesion over the later aspect of 
his knee. Serology for Lyme disease was negative on ELISA 
testing. He was treated with oral doxycycline with prompt 
resolution of his rash and symptoms.
Classic bull's eye EM with initial misdiagnosis as urinary tract  infection Figure 6
Classic bull's eye EM with initial misdiagnosis as uri-
nary tract infection. A 78 year old women presented to an 
urgent care center with 3 days of fever, mild headache and 
the absence of rhinitis, cough or typical upper respiratory 
viral symptoms. The physical exam showed a temperature of 
102 degrees Fahrenheit and a skin rash was not noted. Uri-
nalysis showed 5–10 WBCs, a diagnosis of pylonephritis was 
made, and ciprofloxacin was initiated. The patient returned 
the following day when she noticed a large, red rash on her 
side. The patient was referred to one of the authors (JA) 
who confirmed the diagnosis of Lyme disease. Ciprofloxacin 
was discontinued, doxycycline initiated and the rash 
resolved. Serology returned with a positive ELISA and con-
firmatory western blot.BMC Infectious Diseases 2009, 9:79 http://www.biomedcentral.com/1471-2334/9/79
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rently do not have access to culture or PCR and must rely
as we did on clinical experience when evaluating potential
EM rashes. In addition, the referral population may be
biased toward more complicated acute cases than are typ-
ically seen in a community population. Since patients
were drawn exclusively from Maryland, results may not be
generalizable to other regions where experience with
Lyme diagnosis may be higher, or rates of co-infection
with other tick-borne agents vary. Finally, focusing solely
on those patients referred for possible acute Lyme disease
fails to capture the complexity of addressing those
patients referred with chronic symptoms and more com-
plicated medical histories.
Until more accurate tests are developed for early Lyme dis-
ease, cases without a diagnostic EM rash will need to be
managed carefully. In patients with cutaneous lesions
where the differential diagnosis of cellulitis is not certain,
empiric antibiotics should be chosen that will have activ-
ity against both Lyme disease and common agents of cel-
lulitis [42]. In patients with viral-like illness, the clinician
has the option of obtaining acute and convalescent serol-
ogies without treatment, or treating empirically with dox-
ycycline, advantageously covering other tick-borne
infections such as Rocky Mountain spotted fever or ana-
plasmosis [42]. Again, it should be noted that convales-
cent serology may be falsely negative in patients exposed
to antibiotic treatment early in the course of Lyme disease
[39].
Conclusion
This case series identifies several challenges faced by prac-
titioners in high-risk communities, challenges which may
not be apparent from patients selected for treatment trials,
or in non-urgent, tertiary referral centers. Diagnosing
Lyme disease continues to depend on experience with
accurate identification of typical and atypical EM, and
confirmatory testing in early Lyme disease continues to be
problematic for community clinicians. Our experience
suggests that a significant percentage of cases may show
alternative presentations, resulting in inaccurate diagnosis
and the use of ineffective antibiotics or steroids. Despite a
recent emphasis on curbing over-diagnosis of Lyme dis-
ease, these findings suggest that in non-research settings
of high-risk communities, the possibility of misdiagnosis
may be underestimated by the medical community. Reli-
ance on previous CDC criteria [8] for clinical diagnosis
may lead to under-diagnosis of early cases, and commu-
nity clinicians should be made aware both of recent guide-
line changes and their limitations in individual diagnosis.
Awareness of recent CDC surveillance case definition
diagnostic guideline changes [9] and their limitations,
awareness of alternative clinical presentations, an appreci-
ation for the varied manifestations of EM, and the appro-
priate use of serologic testing will be necessary to reverse
this trend.
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